Literature DB >> 9713677

Augmentation of hormonal activities with antibodies from cattle immunized with a combination of synthetic and recombinant growth hormone peptide.

B S Wang1, D J Search, A A Lumanglas, J Ingling, M J Corbett, H M Shieh, L A Kraft.   

Abstract

Antibodies generated against a synthetic growth hormone (GH) peptide in a number of animal species were shown to enhance the efficacy of GH. However, the ability to produce the effective antibodies diminished over time and repeated boosters failed to overcome the hurdle. Therefore, this study was designed to address the issue on the failed antibody responses by employing different GH peptide antigen preparations in cattle. Holstein steers were repeatedly immunized with a synthetic peptide corresponding to an amino acid sequence 54-95 of porcine GH (pGH). The peptide was conjugated to ovalbumin (OVA) as a carrier. Animals initially responded to the antigen well and elicited antibodies specific to the peptide. However, the 4th challenge with the same OVA-peptide antigen rendered animals unresponsive, resulting in a decline in antibody production. This unresponsiveness was overcome by switching the antigen at the 5th immunization from OVA-peptide to a recombinant peptide preparation which was composed of maltose binding protein (MBP) as a carrier. Antibodies generated in cattle after the 5th immunization recognized not only the pGH(54-95) peptide, but also bovine GH (bGH) and pGH. These antibodies were not immunoreactive with an unrelated control peptide. Hypophysectomized (hypox) rats were used for functional analysis and bGH was active in promoting the growth of these GH-deficient rats. The growth-promoting effect of bGH was significantly enhanced by mixing it with bovine anti-peptide antibodies prior to administration. Therefore, the present findings suggest that peptide 54-95 induces cattle to elicit antibodies capable of not only recognizing bGH but also augmenting the somatogenic effectiveness of bGH in hypox rats.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713677     DOI: 10.1080/10495399809525899

Source DB:  PubMed          Journal:  Anim Biotechnol        ISSN: 1049-5398            Impact factor:   2.282


  2 in total

1.  Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab.

Authors:  S Mojtahed Poor; T Ulshöfer; L A Gabriel; M Henke; M Köhm; F Behrens; G Geisslinger; M J Parnham; H Burkhardt; S Schiffmann
Journal:  Clin Exp Immunol       Date:  2019-02-03       Impact factor: 4.330

2.  Effect of exogenous circulating anti-bPL antibodies on bovine placental lactogen measurements in foetal samples.

Authors:  Andrea Vivian Alvarez-Oxiley; Noelita Melo de Sousa; Jean-Luc Hornick; Kamal Touati; Gysbert C van der Weijden; Marcel Am Taverne; Otto Szenci; Jean-François Beckers
Journal:  Acta Vet Scand       Date:  2010-02-03       Impact factor: 1.695

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.